- Home
- HKD vs COGT Comparison
HKD vs COGT Comparison
Compare HKD & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HKD
- COGT
- Stock Information
- Founded
- HKD 2003
- COGT 2014
- Country
- HKD France
- COGT United States
- Employees
- HKD N/A
- COGT N/A
- Industry
- HKD Finance: Consumer Services
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- HKD Finance
- COGT Health Care
- Exchange
- HKD Nasdaq
- COGT Nasdaq
- Market Cap
- HKD 663.1M
- COGT 555.6M
- IPO Year
- HKD 2022
- COGT 2018
- Fundamental
- Price
- HKD $2.07
- COGT $5.44
- Analyst Decision
- HKD
- COGT Buy
- Analyst Count
- HKD 0
- COGT 6
- Target Price
- HKD N/A
- COGT $15.20
- AVG Volume (30 Days)
- HKD 1.0M
- COGT 1.2M
- Earning Date
- HKD 01-01-0001
- COGT 05-06-2025
- Dividend Yield
- HKD N/A
- COGT N/A
- EPS Growth
- HKD 9.93
- COGT N/A
- EPS
- HKD 0.23
- COGT N/A
- Revenue
- HKD $20,445,000.00
- COGT N/A
- Revenue This Year
- HKD N/A
- COGT N/A
- Revenue Next Year
- HKD N/A
- COGT N/A
- P/E Ratio
- HKD $8.98
- COGT N/A
- Revenue Growth
- HKD N/A
- COGT N/A
- 52 Week Low
- HKD $1.65
- COGT $3.72
- 52 Week High
- HKD $5.80
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- HKD 48.48
- COGT 56.27
- Support Level
- HKD $1.93
- COGT $4.80
- Resistance Level
- HKD $3.44
- COGT $4.99
- Average True Range (ATR)
- HKD 0.22
- COGT 0.31
- MACD
- HKD 0.01
- COGT 0.07
- Stochastic Oscillator
- HKD 9.27
- COGT 88.56
About HKD AMTD Digital Inc. (every five of which represent two)
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment, hotel operations, hospitality and VIP services segment and media and entertainment services. The company generates maximum revenue by providing financial digital solutions through its insurance brokerage services and other digital solutions services. Geographically, the company generates maximum revenue from Hong Kong and Singapore.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.